Local administration of ramiprilat is less effective than oral ramipril in preventing restenosis after balloon angioplasty in an animal model

Journal of Vascular and Interventional Radiology

Volumn 10, Issue 10, 1999, Pages 1397-1404

  Kalinowski, Marc ^a   Tepe, Gunnar ^a   Schieber, Andrea ^a   Brehme, Ute ^a   Bruck, Birgit ^a   Erley, Christiane M ^a   Claussen, Claus D ^a   Duda, Stephan H ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Angioplasty, restenosis; Ramipril

Indexed keywords

RAMIPRIL; RAMIPRILAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; INTRAARTERIAL DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RABBIT; RESTENOSIS; RISK BENEFIT ANALYSIS;

EID: 0032800930     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1051-0443(99)70251-4     Document Type: Article

References (46)

1. Krepel VM, van Andel GJ, van Erp WFM, Breslau PJ. Percutaneous transluminal angioplasty of the femoropopliteal artery: initial and long term results. Radiology 1985; 156: 325-328.
2. Lincoff AM, Topol EJ, Ellis SG. Local drug delivery for the prevention of restenosis; fact, fancy and future. Circulation 1994; 90:2070-2084.
3. Duda SH, Huppert PE, Arndt V, Wehrmann M, Haase K, Claussen CD. In vitro and clinical feasibility study with an over the wire delivery system for pulsed dye laser angioplasty. JVIR 1992; 3:59-63.
4. Fishman DL, Leon MB, Baim DS, et al. Randomized comparison of coronary stent placement and balloon-angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331:496-501.
5. Herrman JP, Hermans WR, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty; the search for the holy grail? (Part I). Drugs 1993; 46:8-52.
6. Marcator Investigators. ACE-Inhibition and restenosis: the final results of the Marcator Trial [abstract]. Circulation 1992; 86:153.
7. Mercator Study Group. Does the new ACE-inhibitor cilazapril prevent restenosis after PTCA? Circulation 1992; 86:100-110.
8. Dusting GJ, Hyland R, Hickey R, Makdissi M. Angiotensin converting enzyme inhibitors reduce neointimal thickening and maintain endothelial nitric oxide function in rabbit carotid arteries. Am J Cardiol 1995; 76:24E-27E.
9. Powell JS, Glozel JP, Muller RKM, et al. Inhibitors of ACE prevent myointimal proliferation after vascular injury. Science 1989; 245:186-188.
10. Powell JS, Muller RKM, Baumgartner HR. Suppression of the vascular response to injury: the role of angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 1991; 17:137B-142B.
11. Becker RHA, Wiemer G, Linz W. Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol 1991; 18(Suppl):S110-S115.
12. Riezebos J, Vleeming W, Beems RB, et al. Comparison of the anti-atherogenic effects of isradipine and ramipril in cholesterol-fed rabbits. J Cardiovasc Pharmacol 1994; 23: 415-423.
13. Nunes GL, Thomas CN, Hanson SR, Barry JJ, King SB, Scott NA. Inhibition of platelet-dependent thrombosis by local delivery of heparin with a hydrogel coated balloon. Circulation 1995; 92:1697-1700.
14. Herdeg C, Oberhoff M, Baumbach A, et al. Local drug delivery with porous balloons in the rabbit: assessment of vascular injury for an improvement of application parameters. Cathet Cardiovasc Diagn 1997; 41:308-314.
15. Hong MK, Wong SC, Farb A, et al. Localized drug delivery in atherosclerotic arteries via a new balloon angioplasty catheter with intramural channels for simultaneous local drug delivery. Cathet Cardiovasc Diagn 1995; 34:263-270.
16. Gonschior P, Goetz AE, Huehns TY, Höfling B. A new catheter for prolonged local drug application. Coron Artery Dis 1995; 6:329-334.
17. Wilensky RL, March KL, Gradus-Pizlo I, et al. Regional and arterial localization of radioactive microparticles after local delivery by unsupported or supported porous balloon catheters. Am Heart J 1995; 129: 852-859.
18. Consigny PM, Miller KT. Drug delivery into the arterial wall: a time course study with the use of a lipophilic dye. JVIR 1994; 5:731-737.
19. Bartorelli AL, de Cesare NB, Kaplan AV, et al. Local heparin delivery prior to coronary stent implantation: acute and six-month clinical and angiographic results. Cathet Cardiovasc Diagn 1997; 2:313-320.
20. Mitchel JF, Barry JJ, Bow L, Alberghini TA, Abbas SA, McKay RG. Local urokinase delivery with the channel balloon: device safety, pharmacokinetics of intracoronary drug delivery, and efficacy of thrombolysis. Cathet Cardiovasc Diagn 1997; 41:254-260.
21. Mitchel JF, Azrin MA, Fram DB, Bow LM, MacKay RG. Localized delivery of heparin to angioplasty sites with iontophoresis. Cathet Cardiovasc Diagn 1997; 41:315-323.
22. Muller DWM, Topol EJ, Abrams GD, Gallagher KP, Ellis SG. Intramural metothrexate therapy for the prevention of neointimal thickening after balloon angioplasty. J Am Coll Cardiol 1992; 20:460-466.
23. Hong MK, Wong SC, Farb A, et al. Feasibility and drug delivery efficiency of a new balloon angioplasty catheter capable of performing simultaneous local drug delivery. Coron Artery Dis 1993; 4:1023-1027.
24. Wilensky RL, Gradus-Pizlo I, March KL, Sandusky GE, Hathaway DR. Efficacy of local intramural injection of colchicine in reducing restenosis following angioplasty in the atherosclerotic rabbit model. Circulation 1992; 86:52-57.
25. Azrin MA, Mitchel JF, Fran DB, et al. Decreased platelet deposition and smooth muscle cell proliferation after intramural heparin delivery with hydrogel coated balloons. Circulation 1994; 90:433-441.
26. Dev V, Lambert T, Sheth S, Eigler N, Forrester J, Litrak F. Kinetics of drug delivery to the arterial wall via polyurethane coated removable nitinol stent-cooperative study of 2 drugs [abstract]. Circulation 1993; 88:1310.
27. Markou CP, Brown JE, Pursley MD, Hanson SR. Boundary layer drug delivery using a helical catheter. J Controlled Release 1998; 53:281-288.
28. Goldman B, Blanke H, Wolinsky H. Influence of pressure on permeability of normal and diseased muscular arteries to horseradish peroxidase: a new catheter approach. Atherosclerosis 1987; 65:215-225.
29. Lambert CR, Leone JF, Howland SM. Local drug delivery. Functional comparison of porous and microporous designs. Coron Artery Dis 1993; 5:469-475.
30. Mitchel JF, Fram DB, Palme DF, et al. L Enhanced intracoronary thrombolysis with urokinase using a novel, local drug delivery system. Circulation 1995; 91:785-793.
31. Plante S, Dupuis G, Mongeau CJ, Durand P. Porous balloon catheters for local delivery: Assessment of vascular damage in a rabbit iliac angioplasty model. J Am Coll Cardiol 1994; 24:820-824.
32. Wilensky R, March L, Hathaway D. Direct intraarterial wall injection of microparticles via catheter: a possible drug delivery strategy following angioplasty. Am Heart J 1991; 22: 1131-1140.
33. Wolinsky H, Thung SN. Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. J Am Coll Cardiol 1990; 15:475-481.
34. Mitchel JF, Azrin MA, Fram DB, et al. Inhibition of platelet deposition and lysis of intracoronary thrombus during balloon angioplasty using urokinase-coated balloons. Circulation 1994; 90:1979-1988.
35. Tsukada T, Rosenfeld M, Ross R, Gown AM. Immunocytochemical analysis of cellular components in atherosclerotic lesions: use of monoclonal antibodies with the Watanabe and fat-fed rabbit. Atherosclerosis 1986; 6:601-613.
36. Hadeishi H, Mayberg MR, Seto M. Local application of calcium antagonists inhibits intimai hyperplasia after arterial injury. Neurosurgery 1994; 34:114-121.
37. Muller DWM, Topol EJ, Abrams GD, Gallagher KP, Ellis SG. Intramural methotrexate therapy for the prevention of neointimal thickening after balloon angioplasty. J Am Coll Cardiol 1992; 20:460-466.
38. Strauss HB, Wilson RA, van Houten R, et al. Late effects of locally delivered mitomycin C on formation of neointima and on vasomotor response to acetylcholine. Coron Artery Dis 1994; 5:633-641.
39. Erley CM, Haefele U, Heyne N, Braun N, Risler T. Microalbuminuria in essential hypertension-Reduction by different antihypertensive drugs. Hypertension 1993; 21: 810-815.
40. Davies MG, Klyachkin ML, Barber L, Svendsen E, Hagen PO. Ramipril and experimental vein graft intimal hyperplasia. Angiology 1995; 46:91-97.
41. Donaubauer H, Mayer D. Acute, subchronic and chronic toxity of the new angiotensin converting enzyme inhibitor ramipril. Arzneimittel-Forschung Drug Res 1988; 38:14-20.
42. Rakugi H, Wang SD, Dzau VJ, Pratt RE. Potential importance of tissue ACE-inhibition in preventing neointima formation. Circulation 1994; 90:449-455.
43. Fingerle J, Muller RM, Kuhn H, Pech M, Baumgartner RM. Mechanism of inhibition of neointimal formation by the angiotensin converting enzyme cilazapril: a study in balloon-injured rat carotid arteries. Arterioscler Thromb Vasc Biol 1995; 15:1945-1950.
44. Penn MS, Saidel GM, Chisolm GM. Relative significance of endothelium and internal elastic lamina in regulating the entry of macromolecules into arteries in vivo. Circ Res 1994; 74:74-82.
45. Kimura T, Miyauchi K, Yamagami S, Daida H, Yamaguchi H. local delivery infusion pressure is a key determinant of vascular damage and intimal thickening. Jpn Circ J 1998; 62:299-304.
46. Schwartz RS, Topol EJ, Serrys PW, Sangiorgi G, Holmes DR. Artery size, neointima, and remodeling. J Am Coll Cardiol 1998; 32:2087-2094.